BeyondSpring Inc.
BYSIHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeBeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. Valued at $17.7M, BYSI is a micro-cap name in its sector. The company operates through two segments: the Plinabulin pipeline and the TPD platform.
Market Cap
$17.7M
Beta
-0.21
P/E (TTM)
—
P/E (Fwd)
-0.92
EPS (TTM)
$-0.18
EPS (Fwd)
$-0.47
ROE
—
ROA
-22.9%
Cash
$6.5M
Total Debt
$171,000
Free CF
$10.7M
52W Change
-78.6%
Annual Financials
Cash vs Debt
Where BYSI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BYSI finished 59.52% below its 150-day moving average ($1.26) and 61.36% below its 200-day moving average ($1.32). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BYSI overbought or oversold?
At the October 20, 2026 close, BYSI's RSI(14) was 14.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
BeyondSpring Inc. holds $6.5M in cash against $171K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $10.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Revenue has pulled back from $1.4M (2022) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, BeyondSpring Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, BYSI has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing BYSI's risk profile alongside its fundamentals and technical indicators provides a more complete picture.